Opinion|Videos|November 22, 2024
Optimal Dosing Strategies and Managing AEs
Panelists discuss how they dose talquetamab in clinical practice, comparing its administration schedule to other bispecific antibodies and addressing dosing-related challenges they encounter.
Advertisement
Episodes in this series
Video content above is promoted by the following;
- Briefly discuss your case details and share your initial thoughts.
- How are you currently dosing talquetamab?
- How does the dosing for talquetamab compare with other bispecifics?
- What are the challenges you are seeing?
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
3
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5